Adamax
Next-Generation Semax Derivative | Nootropic Neuropeptide
Community Research
Join others researching Adamax — share findings, ask questions, and learn from real experiences
Synthetic nootropic peptide with N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration, researched for cognitive enhancement, neuroprotection, and neuroplasticity.
Crosses BBB via enhanced lipophilicity from adamantane; upregulates BDNF and TrkB receptor sensitivity; modulates dopamine, norepinephrine, and serotonin; stabilizes microtubules via ADNP-derived mechanisms; provides antioxidant and anti-inflammatory neuroprotection.
Molecular Data
?MEHFPGP??Ac
Position 1
Methionine
Position 2
Glutamic Acid
Position 3
Histidine
Position 4
Phenylalanine
Position 5
Proline
Position 6
Glycine
Position 7
Proline
Position 8
AGly
Position 9
NH2
Position 10
Research Indications
Preliminary research suggests improvements in focus, mental clarity, memory consolidation, and complex task handling.
BDNF upregulation and TrkB enhancement promote new neural connections and synaptic plasticity for long-term improvements.
May enhance memory formation, information retention, and learning efficiency through hippocampal BDNF-TrkB pathway activation.
Preliminary observations indicate improved neurological outcomes through oxidative stress reduction and neuronal repair.
Demonstrates antioxidant properties protecting against oxidative damage and inflammation-induced neuronal injury.
Supports neuronal survival and growth through BDNF enhancement and microtubule stabilization.
Influences serotonin and dopamine to elevate mood and reduce depressive symptoms through neurotransmitter modulation.
Anecdotal reports indicate reduced overwhelm and anxiety through balanced neurotransmitter activity.
HPA axis modulation may improve stress response and emotional well-being.
Dosing Protocols
Enhanced cognitive function and neuroprotection through direct systemic delivery with superior bioavailability.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Cognitive Enhancement | 200-300mcg | 1x daily | SubQ |
| Neuroprotection | 300mcg | 1-2x daily | SubQ |
| Mood Support | 200mcg | 1x daily (morning) | SubQ |
| Initial Trial | 100-200mcg | 1x daily | SubQ |
Reconstitution Instructions
- Bacteriostatic water (BAC)
- Insulin syringes (0.5-1mL)
- Alcohol swabs
- Peptide vial
- Sterile work surface
- 1 Clean work area and hands thoroughly with alcohol
- 2 Calculate required BAC water volume using calculator
- 3 Draw calculated BAC water into syringe
- 4 Inject slowly down vial side (not directly onto powder)
- 5 Gently swirl until completely dissolved (never shake vigorously)
- 6 Store reconstituted solution in refrigerator at 2-8°C
- 7 Use within 14-30 days for optimal potency
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Headaches (particularly at higher doses)
- Insomnia or sleep disruption
- Anxiety or overstimulation
- Cardiovascular effects (elevated blood pressure, palpitations)
Stop Signs - Discontinue if:
- Persistent or severe headaches
- Chest pain, heart palpitations, or significant blood pressure increases
- Severe anxiety, insomnia, or mood disturbances
- Unusual neurological symptoms or mental status changes
- Persistent injection site reactions or infection signs
- Gastrointestinal distress (nausea, vomiting, diarrhea)
Contraindications
- Pregnancy and breastfeeding
- Cardiovascular conditions (without medical supervision)
- Severe anxiety disorders
- Uncontrolled hypertension
Quality Checklist
Good Signs
- White, fluffy powder indicating proper freeze-drying
- Clear solution after reconstitution with no particles or cloudiness
- Proper labeling with peptide name, batch number, manufacturing date
Warning Signs
- Slight compaction from shipping acceptable if powder dissolves completely
Bad Signs
- Discoloration or yellowing indicates oxidation or degradation
- Persistent cloudiness or particles indicate degradation or contamination
References
- A Nootropic Adrenocorticotropin Analog 4-10 Semax: 15 Years Experience in Its Design and Study (Parent Compound)Ashmarin IP, Nezavibatko VN, Levitskaya NG, et al.Zhurnal Vysshei Nervnoi Deiatelnosti imeni I.P. Pavlova (1997)
Foundational Semax review: intranasal doses stimulate operative memory and attention for 20-24 hours. Adamax builds on the Semax core sequence with adamantane modification for enhanced stability and BBB penetration.
- Semax, an Analog of ACTH(4-10), Regulates BDNF and trkB Expression in the Rat Hippocampus (Parent Compound)Dolotov OV, Karpenko EA, Inozemtseva LS, et al.Brain Research (2006)
Single application at 50 mcg/kg produced 1.4-fold increase in BDNF protein and 1.6-fold increase in trkB tyrosine phosphorylation in rat hippocampus, supporting Adamax's BDNF-TrkB mechanism.
- The Efficacy of Semax in the Treatment of Patients at Different Stages of Ischemic Stroke (Parent Compound)Gusev EI, Barskov IV, et al.Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (2018)
110 ischemic stroke patients; Semax (6000 mcg/day intranasal) increased BDNF plasma levels and accelerated functional recovery, providing the clinical basis for Adamax neuroprotective applications.
- The Peptide Semax Affects the Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischemia (Parent Compound)Dergunova LV, Limborska SA, et al.BMC Genomics (2014)
Genome-wide analysis: Semax modulated 24 vascular genes at 3h and enhanced immune-response gene expression at 24h post-ischemia, demonstrating multi-pathway neuroprotection.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.